Immutep's IMP761 Shows Positive Results in Autoimmune Disease Trial.

Immutep Limited reports positive results from the first-in-human Phase I study of IMP761, a LAG-3 agonist antibody for autoimmune diseases. The single-ascending dose portion of the trial has reached 2.5 and 7 mg/kg levels, showing a dose-dependent immunosuppressive effect and favorable safety profile. The substantial reduction in T-cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases. The trial will continue as planned, with further updates and data presentation anticipated in 1H CY2026.